# CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

> **NCT04676334** · PHASE3 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer
- Ovarian Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
- Other Solid Tumor

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT04676334
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-22
- **Primary completion:** 2023-03-08
- **Final completion:** 2023-03-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676334, "CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04676334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*